Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; and Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection.
Additionally, the company provides the GuardantINFINITY Test that offers insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development. GuardantConnect is an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. The GuardantOMNI blood test is intended for advanced stage cancer, while GuardantINFORM serves as an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Guardant Health also offers the Shield Test; the Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and the Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests.
The company was incorporated in 2011 and is headquartered in Palo Alto, California.
